In plain language
In 134 transcatheter atrial septal defect closures, using 4 instead of 7.5 fluoroscopy frames per second cut patient air kerma and dose area product by about two thirds with similar success. Staff dose was not measured but would likely fall too.
At a glance
- Type of study
- Original research, Retrospective cohort study
- Who was studied
- Patients
- Size
- n = 134 procedures
- Summary based on
- the abstract
What it found
Median total air kerma was lower with 4 frames per second than with 7.5 frames per second.
Key figures: 4 versus 1.3 mGy [p=0.00012]
Median dose area product was lower with 4 frames per second.
Key figures: 43.7 versus 13.1 μGy.m2
Procedural success was similar between frame rates.
Key figures: 100 versus 98.8%
Authors recommend adopting the lower frame rate to reduce exposure to patients and laboratory personnel.
Limits to keep in mind
Single-centre retrospective comparison of 134 procedures using patient dose metrics only; staff exposure was not measured and the country and patient ages are not stated in the abstract.
Related research summaries
- Fluoroscopy-minimization strategy for catheter ablation of Supraventricular Tachycardia by wOmen OPerators: the STOOP Multicentre Registry (2026, Prospective cohort study)
- Two Central Nervous System Tumors in One Catheter Lab: Time to Rethink Radiation Protection (2026, Retrospective cohort study)
- Radiation Awareness for EVAR in Hybrid Operating Room: An Instant Operator Risk Chart (2021, Dosimetry measurement study)
- Utilization of a Radiation Safety Time-Out Reduces Radiation Exposure During Electrophysiology Procedures (2019, Prospective cohort study)
- Completely nonfluoroscopic catheter ablation of left atrial arrhythmias and ventricular tachycardia (2018, Case report or series)
How this summary was made
ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.
Prepared November 3, 2026.